Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma

Summary

This phase II trial studies how well eribulin mesylate works in treating patients with osteosarcoma that has come back after treatment (recurrent) or has not responded to treatment (refractory). Microtubule inhibitors, such as eribulin mesylate, may stop or slow the growth of tumor cells by disrupting the cell cycle.

Timeline

Start

2014-08

Primary completion

2015-06-30

Completion

2020-03-31

Drugs

Indications